Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v, a Universal Mosquito-Borne Disease Vaccine   NIAID Protocol Number 17-I-0059   Sponsored by [CONTACT_916] (OCRPRO), DCR, NIAID, NIH  IND # [ZIP_CODE]  Vaccine Manufactured by [CONTACT_818546] J. Memoli, MD, MS  Version Number and Date Version 5.0 February 09, 2018  
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 2 of 62 TEAM ROSTER  Principal Investigators  Matthew J. Memoli, MD, MS Director, Clinical Studies Unit LID, NIAID Building 33, Room 3E19A Bethesda, MD [ZIP_CODE] Tel: [PHONE_17093] Email: [EMAIL_1593]      Associate Investigators     Jesus G. Valenzuela, PhD LMVR, VMBS, NIAID Tel: [PHONE_17094] Email: [EMAIL_792]  Jessica Manning, MD, MS LID, NIAID Tel: [PHONE_17095] Email: [EMAIL_15565]  Shaden Kamhawi, PhD LMVR, VMBS, NIAID Tel: [PHONE_17094] Email: [EMAIL_1594]  Luiz Fabiano Oliveira, MD PhD LMVR, VMBS, NIAID Tel: [PHONE_17096] Email: [EMAIL_15566]  Iliano V. Coutinho-Abreu, PhD LMVR, VMBS, NIAID Tel: [PHONE_17097] Email:[EMAIL_1597]   Study Statistician Sally Hunsberger, PhD Mathematical Statistician  Biostatistics Research Branch  National Institute of Allergy and Infectious Diseases / NIH / U.S. DHHS Tel:  [PHONE_716] Email: [EMAIL_789]   
Universal Mosquito Vaccine Protocol Version 5.[ADDRESS_1133684] Frederick, MD [ZIP_CODE] Tel: [PHONE_715] Email: [EMAIL_15567]   Study Staff NIH Holly Ann Baus, RN, MSN LIR, NIAID Tel: [PHONE_17098] Email: [EMAIL_1600]    Susan M. Reed, BA, CRC LID, NIAID Tel: [PHONE_17099]   Rani S. Athota, BS, MPH LID, NIAID Tel: [PHONE_17100]    Unblinded Study Staff NIH      Alison Han, MD, MS      LID, NIAID      Tel: [PHONE_17101]      Email: [EMAIL_1595]       Lindsay M. Czajkowski, MSN, NP-C      LID, NIAID Tel: [PHONE_17102]    Collaborators  Kathie-Anne Walters, PhD Institute for Systems Biology [ADDRESS_1133685] N Seattle, WA [ZIP_CODE] Tel: [PHONE_17103] Email: [EMAIL_15568]     
Universal Mosquito Vaccine Protocol Version 5.[ADDRESS_1133686] OF ABBREVIATIONS .............................................................................................. 7	PROTOCOL SUMMARY .................................................................................................. 8	1	BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE ..................... 12	2	STUDY OBJECTIVES ......................................................................................... 21	2.1	Primary Objective ................................................................................................ 21	2.2	Secondary Objectives ......................................................................................... 21	3	STUDY DESIGN ................................................................................................. 22	3.1	Description of the Study Design .......................................................................... 22	3.2	Study Endpoints .................................................................................................. 22	4	STUDY POPULATION ........................................................................................ 23	4.1	Rationale for Participant Selection ...................................................................... 23	4.2	Recruitment Plan ................................................................................................. 24	4.3	Inclusion Criteria ................................................................................................. 24	4.4	Exclusion Criteria ................................................................................................ 25	4.5	Justification for Exclusion of Pregnant Women and Children (Special Populations) ........................................................................................................ 26	5	STUDY AGENTS/INTERVENTIONS .................................................................. 26	5.1	Agent 1: AGS-v, AGS-v + Adjuvant, or Placebo ................................................. [ADDRESS_1133687] Accountability ............................................................................. 29	5.3.2	Accountability of Study Supplies ............................................................. 30	5.3.3	Retention of Samples .............................................................................. 30	5.4	Concomitant Medications and Procedures ......................................................... 30	6	STUDY SCHEDULE ........................................................................................... 30	6.1	Randomization and Blinding ............................................................................... 31	6.2	Randomization and Vaccine or Placebo Administration (Day 0) ......................... 31	6.3	Day 7 (+/- 2 days) ............................................................................................... 32	6.4	Day 14 (+/- 2 days) ............................................................................................. 32	6.5	Day 21 (+/- 2 days) ............................................................................................. 33	6.6	Day 28 (+/- 2 days) ............................................................................................. 33	6.7	Day 35 (+/- 2 Days) ............................................................................................. 33	6.8	Day 42 Mosquito Feeding (+14 days) ................................................................. 34	6.9	Day 44 Telephone Call (+/- 1 day) ...................................................................... 35	6.10	Follow-up ............................................................................................................. 35	7	STUDY PROCEDURES/ EVALUATIONS .......................................................... 35	7.1	Clinical and Laboratory Evaluations .................................................................... 35	
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 5 of 62 7.1.1	Laboratory Testing of Collected Samples for Primary and Secondary Endpoints ................................................................................................ 35	7.2	Reactogenicity ..................................................................................................... 37	8	POTENTIAL RISKS AND BENEFITS ................................................................. 37	8.1	Risks of Placebo administration .......................................................................... 37	8.2	Risks of AGS-v ± adjuvant vaccination ............................................................... 37	8.3	Risks of adjuvant ................................................................................................. 39	8.4	Risks of blood draw ............................................................................................. 40	8.5	Risks of Aedes aegypti Mosquito Feeding .......................................................... 41	8.6	Potential Benefits ................................................................................................ 41	9	RESEARCH USE OF STORED HUMAN SAMPLES, SPECIMENS, OR DATA 41	10	DATA SHARING PLAN ....................................................................................... 42	10.1	Human data generated in this study will be shared for future research as follows: ............................................................................................................................ 42	10.2	Data will be shared through ................................................................................ 42	10.3	The data will be shared: ...................................................................................... 42	11	REMUNERATION PLAN ..................................................................................... 42	12	ASSESSMENT OF SAFETY ............................................................................... 43	12.1	Documenting, Recording, and Reporting AEs .................................................... 43	12.2	Definitions ........................................................................................................... 43	12.3	Investigator Assessment of AEs ......................................................................... 45	12.3.1	Severity ................................................................................................... 45	12.3.2	Causality .................................................................................................. 46	12.4	Investigator Reporting Responsibilities to the Sponsor ....................................... 47	12.4.1	AEs .......................................................................................................... 47	12.4.2	SAEs ....................................................................................................... 47	12.4.3	Unanticipated Problems .......................................................................... 47	12.4.4	Pregnancy ............................................................................................... 47	12.5	Investigator Reporting Responsibilities to the NIAID IRB ................................... 48	12.5.1	Special Reporting Situations ................................................................... 48	12.5.2	Expedited Reporting to the NIAID IRB .................................................... 48	12.5.3	Waiver of Reporting Anticipated Protocol Deviations, Expected UPnonAEs and Deaths to the NIAID IRB ................................................ 48	12.5.4	Annual Reporting to the NIAID IRB ......................................................... 48	12.6	Follow-Up of AEs and SAEs ............................................................................... 49	12.7	Sponsor’s Reporting Responsibilities .................................................................. [ADDRESS_1133688] .............................................................. 49	12.8.1	Reporting a Pause ................................................................................... 50	12.8.2	Resumption of a Paused Study ............................................................... 50	12.9	Halting Rules for the Protocol ............................................................................. 50	12.9.1	Reporting a Study Halt ............................................................................ 50	12.9.2	Resumption of a Halted Study ................................................................. 50	12.10	Study Discontinuation ......................................................................................... 51	12.11	Premature Withdrawal of a Participant ................................................................ 51	12.12	Replacement of a Participant .............................................................................. 52	12.13	Safety Oversight .................................................................................................. 52	12.13.1	Safety Review and Communications Plan (SRCP) ................................. [ADDRESS_1133689] .......................................................... 52	13	SITE MONITORING PLAN ................................................................................. 53	
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 6 of 62 14	STATISTICAL CONSIDERATIONS .................................................................... 53	14.1	Study Hypothesis ................................................................................................ 53	14.2	Sample Size Justification and Analysis Plan ....................................................... 53	14.3	Analysis Plan ....................................................................................................... 55	15	ETHICS/PROTECTION OF HUMAN PARTICIPANTS ....................................... 55	15.1	Informed Consent Process .................................................................................. 55	15.2	Non–English-Speaking Participants .................................................................... [ADDRESS_1133690] Retention ................................................................................................ 57	APPENDIX A: SCHEDULE OF PROCEDURES/EVALUATIONS .................................. 61	APPENDIX B: BLOOD VOLUMES FOR SPECIMEN COLLECTION ............................. [ADDRESS_1133691] one AE. .......................................................... 54	Table 3. Difference in probabilities that can be detected with 80% power for sample sizes of [ADDRESS_1133692] of Figures Figure 1. Graph representing the mosquito % survival post feeding .............................. [ADDRESS_1133693] of immunization with salivary gland protein fractions on mosquito fecundity. (vehicle (control), <20 kDa, 20-40 kDa, 40-80 kDa and >80 kDa) fecundity. .......................................................................................................... 16	Figure 3. IFN-g response in mice immunized with AGS-mix  (AGS-v) or vehicle. .......... 17	Figure 4.Total Ig and IgG2a specific-AGS-mix (AGS-v) ................................................. [ADDRESS_1133694]  ECG  Electrocardiogram ELISA  Enzyme-linked Immunosorbent Assay EP  European Pharmacopoeia FDA  Food and Drug Administration GCP  Good Clinical Practice HIV  Human Immunodeficiency Virus HRPP  Human Research Protection Program ICH  International Council on Harmonization IFA  Incomplete Freund’s adjuvant Ig  Immunoglobulin IND  Investigational New Drug IP  Investigational Product IRB  Institutional Review Board IV  Intravenous LID  Laboratory of Infectious Disease NIAID  National Institute of Allergy and Infectious Diseases  NIH  National Institutes of Health OCRPRO Office of Clinical Research Policy and Regulatory Operations OHRP  Office for Human Research Protections PBMC  Peripheral Blood Mononuclear Cell PCR   Polymerase chain reaction PI  [INVESTIGATOR_818533], Unexpected, Suspected Adverse Events Th1  CD4+ T helper (Th1) cells UP  Unanticipated Problem UPnonAE Unexpected Problem that is not an AE USP  [LOCATION_002] Pharmacopeia WFI  Water for Injection 
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 8 of 62 PROTOCOL SUMMARY Full Title:  Randomized, Double-Blind, Placebo-Controlled, Single-center, Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine  Short Title: Universal Mosquito Vaccine  IND Sponsor:   OCRPRO, DCR, NIAID, NIH/ NIAID LID CSU Conducted by:  [CONTACT_818547]: [INVESTIGATOR_40613] J. Memoli, MD, MS Sample Size: 45 participants Accrual Ceiling: 60 participants   Study Population:  Healthy volunteers 18 to 50 years of age Accrual Period:  1 year  Study Design:  This is a randomized, double-blind, placebo-controlled, single-center, Phase 1 study of AGS-v administered as 2 vaccinations prior to a non-infected Aedes aegypti mosquito feeding. Study Duration: The study will begin approximately in December [ADDRESS_1133695] participation is about 1 year. Study Agents  1. AGS-v   2. AGS-v + adjuvant   3. Placebo Intervention Description: Individuals will be vaccinated subcutaneously with vaccine or placebo.    Primary Objective:  The primary objectives of the study are: 1. To determine the safety of AGS-v as measured by [CONTACT_818548] (AEs) observed 2. To identify an immune response produced by [CONTACT_438137]-v by [CONTACT_818549]: a. Total AGS-v specific immunoglobulin from participant serum [ADDRESS_1133696] and/or second vaccination 
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 9 of 62 b. Th1 and Th2-associated cytokine release after incubation of peripheral blood mononuclear cells (PBMCs) collected [ADDRESS_1133697] or second vaccination with AGS-v antigens     Secondary Objectives: The secondary objectives of this study are to identify other measures of immunogenicity including:   1. Measurement of immune response after clean Aedes aegypti mosquito feeding on participants by: a. measuring AGS-v specific total immunoglobulin from serum  b. measuring Th1 and Th2-related cytokines after incubation of PBMCs with AGS-v antigens   2. Measure AGS-v specific immunoglobulins, primarily IgG1, IgG3, and IgM both after vaccination and clean Aedes aegypti mosquito feeding 3. Evaluate the effect of the AGS-v immune response on Aedes aegypti mosquito feeding and fecundity after feeding on a vaccinated individual or whole blood collected from those individuals in vitro.   4. Evaluate the effect of incubating Zika virus coated in vector saliva with PBMCs and/or serum collected from vaccinated individuals. Endpoints:   Primary:  1. Incidence and severity (by [CONTACT_9317]) AEs in AGS-v vaccinated individuals 2. Total AGS-v specific immunoglobulin measured in serum [ADDRESS_1133698] and/or second vaccination. 3. Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of the Th1 vs. Th2 response  
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 10 of 62 Secondary:  1. Total AGS-v specific immunoglobulin in acute serum collected immediately after a clean Aedes aegypti mosquito feeding and convalescent serum collected on follow-up visits (60 days later +/- 14 days)               2. Interferon-gamma and other cytokine markers of a Th1 or Th1/Th2 mixed response measured in vitro from acute PBMCs and serum collected immediately after a clean Aedes aegypti mosquito feeding incubated with AGS-v antigens and convalescent PBMCs and serum collected on follow-up visits (60 days later +/- 14 days) 3. Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination both in vivo and in vitro, including survival, egg laying, and other measures of reproduction. 4. Infectivity of Zika virus after incubation with serum and/or PBMCs from vaccinated participants   
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 11 of 62 Précis Mosquito-borne diseases continue to cause significant morbidity and mortality worldwide despi[INVESTIGATOR_645422]-going control efforts.  In 2015, there were >[ADDRESS_1133699] multiple arboviral and protozoal diseases.  In addition the vaccine potentially leads to a reduced mosquito lifespan after feeding therefore also reducing transmission of these diseases.  In this protocol we hope to demonstrate the safety of this vaccine similar to SEEK’s other peptide based vaccines Flu-v and HIV-v that have been found to have very good safety profiles in previous Phase I trials.  We also hope to demonstrate immunomodulation after a controlled clean Aedes aegypti mosquito feeding to demonstrate proof of concept efficacy of the vaccine. With the current rise of Zika in the Americas and the threat of local mosquito transmission in the U.S. and the rest of the world, a successful universal mosquito-borne disease vaccine offers the benefit of targeting this emerging disease as well as the many established infections such as dengue and malaria that make dealing with this newly emerging epi[INVESTIGATOR_901] a challenge. 
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 12 of 62 1 Background Information and Scientific Rationale  Mosquito-borne diseases continue to cause significant morbidity and mortality worldwide despi[INVESTIGATOR_645422]-going vector control efforts.  In 2015, there were >[ADDRESS_1133700] emerged in Brazil and now includes several countries in Central and South America, the Caribbean, and the U.S. serves as a reminder of how quickly these vector-borne viruses can spread and how difficult they can be to control.  In large parts of Africa, South America and Asia, an estimated 3.2 billion people are at risk of contracting malaria1, and arboviral infections occur worldwide without discrimination between developed and developi[INVESTIGATOR_40620].  Current prevention programs follow a two-prong approach simultaneously controlling mosquito populations by [CONTACT_818550]. For malaria, this approach, along with artemisinin-based combination therapy (ACT), has proven highly successful in locations such as Zanzibar2, but the effective implementation requires continuous investment by [CONTACT_818551], local governments, healthcare systems, and the people living in those communities. Unfortunately, this approach has not always been possible to sustain, as exemplified by [CONTACT_40685] 1950s-1960s3.   Efforts in malaria and arboviral elimination continue to include the development of an effective vaccine that can both prevent the development of the disease in a healthy individual (prophylactic vaccine) and block the transmission of the disease from an infected individual to the insect vector (transmission blocking vaccine). Most attempts at developi[INVESTIGATOR_007] a malaria vaccine have centered on the prophylactic application, but unfortunately they have shown little efficacy.  Even the most successful recent candidate vaccine, RTS,S/AS01 (RTS,S) by [CONTACT_35316], had vaccine efficacy of 27-46% in children and infants, respectively 4. Even if the RTS,S vaccine is licensed, there will be a recognized need for the continued implementation of current malaria prevention programs 5.  
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 13 of 62 In this protocol we propose to perform a Phase I study of a universal mosquito-borne disease vaccine manufactured by [CONTACT_818552].  SEEK sought to create an ideal malaria and arboviral disease vaccine that addresses both the prophylactic and the transmission blocking components.  SEEK’s approach in developi[INVESTIGATOR_40621] a vaccine is defined by [CONTACT_40688]:  • Because the complexity and variability of the pathogens’ life cycle and antigenic make up, the prophylactic effect of the vaccine is not aimed at destroying the parasite itself, but rather to decrease the development of the essential physiologic environment that leads to a successful infection in humans. • Because the varied number of mosquito species capable of transmitting the pathogens, the transmission blocking effect of the vaccine is not aimed at killing the vector on contact, but rather to prevent the very process of blood feeding, which is essential for the successful procreation of the vector. • Because most nations where malaria and arboviral diseases are endemic do not have well developed healthcare systems and limited healthcare budgets, the vaccine must be economically viable as a large-scale product entirely manufactured synthetically from raw components, which are widely available, and must not require complex storage and delivery systems.  Female mosquitoes have an absolute physiological need for blood-feeding in order to produce viable eggs and a healthy offspring. As they probe the skin for blood with their proboscis they salivate into the bite site inoculating parasites (i.e. plasmodium) or arbovirus (i.e., Dengue virus, Zika virus) into their human host.   Mosquito saliva contains a range of molecules including vasodilators, anticoagulants and immunomodulators whose purpose is to prevent the disruption of feeding by [CONTACT_40689] 6. Mosquito saliva has been shown to inhibit T and B cell proliferation 7 and downregulate the expression of interferon gamma (IFN-g) 8, a soluble Th1 pro-inflammatory immune mediator known to have in vivo therapeutic and prophylactic effects against other arthropod transmitted diseases such as leishmaniasis 9. Interestingly, mosquito saliva also triggers a non-inflammatory Th2 immune response in the host that causes the characteristic irritation and allergic reaction associated with mosquito bites 10.  With time and continuous exposure, individuals become desensitized to mosquito bites due to a reduction in Th2 cytokine mediators, thus allowing for the more effective development of pro-inflammatory Th1 responses 11. This process is thought to be associated with the gradual acquisition of partial immunity to infection observed in adults living in malaria-endemic regions. Studies in patients infected by [CONTACT_818553] 5.[ADDRESS_1133701] that an increase of Th1 cytokines (e.g. IL-12 and IFN-g) in the acute phase provides protective immunity and may also be involved in preventing severe malaria and complications from malaria. [ADDRESS_1133702] them (e.g., Leishmania and Plasmodium), but non-activated macrophages are unable to do so. Macrophage activation is characteristic of a Th1 response and is inhibited by [CONTACT_40690]2 response triggered by [CONTACT_40691].  This same process of downregulation of Th1 cytokines by [CONTACT_40692] a Th2 response at the bite by [CONTACT_818554] 19, and arboviruses in general 20.  Beyond its direct effect on the parasite in the human host, an immune response to saliva has been shown to reduce malaria transmission. A monoclonal antibody raised against a [ADDRESS_1133703] salivary antigens may block transmission of these infections not only by [CONTACT_40695], but also by [CONTACT_40696].   Based on the above scientific argument, SEEK’s approach to developi[INVESTIGATOR_007] a vaccine against mosquito-borne pathogens based on the identification of suitable antigenic targets in mosquito saliva capable of inducing, upon vaccination of the mammalian host, a strong anti-mosquito saliva Th1 response would (a) prevent infection by [CONTACT_818555] (b) block transmission of the disease by [CONTACT_818556]’s salivary glands and/or reduce the survival and/or fecundity of the vector.  As indicated earlier, SEEK aims at manufacturing this vaccine by [CONTACT_40698]. However, mosquito saliva contains a multitude of proteins with molecular weights up to and above [ADDRESS_1133704] had to identify suitable vaccine targets in saliva for manufacturing.  This process of target identification started with the simple separation of the proteins of a salivary gland lysate from Anopheles gambiae into fractions according to their molecular weight (i.e. <20 kDa, 20-40 kDa, 40-80 kDa and >80 kDa). These fractions were used to immunize mice upon which uninfected A. gambiae mosquitoes were allowed to feed and the survival and fecundity of these mosquitoes analyzed.  As shown in Fig. 1, immunization with several mosquito salivary gland proteins fractions significantly reduced mosquito survival. The fraction containing proteins below [ADDRESS_1133705] effective, killing 80% of the mosquito population after only [ADDRESS_1133706]-feeding. Fractions containing proteins between 20 and 40 kDa and over 80 kDa also reduced mosquito longevity, but were less effective than the <20 kDa protein fraction. As Plasmodium can complete its mosquito life cycle stage in between 7 to 10 days, the ability of the <20 kDa protein fraction to kill 80% of mosquitoes within 6 days of feeding is important from the transmission blocking point of view as infected mosquitoes will die before they can transmit the disease.    Figure 1. Graph representing the mosquito % survival post feeding 
 Graph representing the mosquito % survival after feeding on mice immunized with different salivary gland protein fractions (vehicle (control), <20 kDa, 20-40 kDa, 40-80 kDa and >80 kDa). Mosquito salivary glands were dissected and their protein content separated by [CONTACT_451]-PAGE according to their molecular weight. Proteins within the MW ranges of interest were recovered from the gel and used to immunize mice. Fresh A. gambiae mosquitoes fed on these mice and were monitored for [ADDRESS_1133707]-feed for survival (N=150 mosquitoes per group).  In addition, immunization with the <20 kDa fraction, and the 20-40 kDa fraction significantly (p<0.05) reduced the number of eggs produced, eggs laid, larvae arising 

Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 16 of 62 from eggs and mature adult offspring by [CONTACT_818557] (Fig. 2). Such reduction in the number of viable offspring would have a significant effect on the number of vectors available for disease transmission at any one time, and hence in the overall transmission rate of the disease.   Figure 2. Effect of immunization with salivary gland protein fractions on mosquito fecundity. (vehicle (control), <20 kDa, 20-40 kDa, 40-80 kDa and >80 kDa) fecundity. 
   From this point, SEEK proceeded to identify the proteins present in the fractions containing proteins <[ADDRESS_1133708] of these proteins were still too large to be chemically synthesized and hence further work was required to identify reactive domains in these proteins that could successfully be manufactured and still retain the desired immunogenicity. This stage of the process was carried out using a computer algorithm developed by [CONTACT_40700]. The algorithm identifies and categorizes T-cell epi[INVESTIGATOR_40622] a protein based on analysis of the structural affinity of a peptide for a given MHC/HLA allele and the reactivity of this complex to T cells. Any small regions (25+ amino acids) within a protein identified by [CONTACT_818558] T cell epi[INVESTIGATOR_40623]-referenced against all available human proteomic data (GeneBank and SwissProt). Any region showing significant sequence similarity was discarded in order to minimize the risk of inducing an autoimmune challenge following immunization. This algorithm and approach have already been successfully applied to the identification of conserved reactive T cell regions in both influenza 24 and HIV viruses. The identified sequences constitute two independent candidate vaccine preparations currently undergoing clinical trials in the [LOCATION_006].  

Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 17 of 62 The selection of reactive T cell regions is based on SEEK’s interest in inducing a specific Th1 response to the salivary proteins. As indicated earlier in this document, a switch from a Th2 to a Th1 immune response to the saliva of the mosquito vector is associated with an increased resistance and natural immunity to malaria infection.  Several reactive regions in salivary proteins of <40 kDa each containing multiple T cell epi[INVESTIGATOR_818534]. A cocktail of these small protein sequences (all less than 8 kDa) and identified as AGS-v (or AGS-mix) were used to immunize mice and to establish the type of induced immune response.  While there is no specific reason why four peptides are needed, the rationale is that the vaccine was developed to be active against a range of hematophagous arthropod vectors (such as Anopheles and Aedes mosquitos).  As shown in Figure 3, immunization with AGS-v induced a strong IFN-g response from immune cells upon recall with the antigen compared to immunization with a control mix of irrelevant peptides. Immunization with AGS-v was also found to induce a strong antibody response to the vaccine candidate (Figure 4), characterized by a significant contribution by [CONTACT_40702]2a isotype. Both IFN-g and IgG2a are considered primary mediators of a Th1 response and hence immunization with AGS-v can and does induce the desired Th1 response.  Figure 3. IFN-g response in mice immunized with AGS-mix  (AGS-v) or vehicle. 
 Splenocytes were isolated from mice spleens and incubated with media (blank), a non-specific positive control (Concanavalin A), or different concentrations of the vaccine preparation (2-4uM AGS-mix). After 72h incubation, the levels of IFN-g (Th1 cytokine) were measured by [CONTACT_6428].   0200400600800100012001400
blankConAAGS-mix 2uMAGS-mix 4uMcontrol groupAGS-mix groupSplenocyte IFNg production
IU/ml 
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 18 of 62 Figure 4.Total Ig and IgG2a specific-AGS-mix (AGS-v)  response in mouse sera as measured by [CONTACT_6428]. 
   Having established that immunization with AGS-v induces a Th1 response in mice, SEEK wanted to establish whether this response was able to reduce the rate of malaria infection in a mouse model of the disease.   Traditional experimental models of malaria infection rely on the intravenous injection of large numbers of parasites in order to successfully establish infection in the mouse. It has been reported that these models do not reflect the natural process of infection by [CONTACT_818559] 25. Interestingly, it has been suggested by [CONTACT_818560], which having been shown to be very effective in such models, did not induce any significant protection when tested in real-life infection conditions. It is for this very reason and the nature of the vaccine candidate that SEEK chose to test the product in a natural model of infection (i.e. via the bite of infected mosquitoes).  Preliminary studies using a natural model of infection involving A. gambiae infected with P. yoelii nigeriensis show that mice vaccinated with AGS-v are more resilient to infection than mice vaccinated with an irrelevant peptide control mix (Figure 5). AGS-v was found to reduce infection rates 4-fold compared to the control group.  antibodies response to AGS-mix
-[IP_ADDRESS].533.5
1:1001:2001:400mouse sera dilutionAbs 450nmAGS-mix immunised total IgAGS-mix immunised IgG2avehic le immunis ed t ot al Igvehic le immunis ed IgG2a
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 19 of 62 Figure 5.Animals succumbing to infection 
  Survival of mice vaccinated with AGS-v vs. mice vaccinated with a control preparation (NRP or non-relevant product) upon challenge via malaria-infected mosquito bite. Groups of 5-6 mice were challenged by [CONTACT_818561] (low to moderate parasite oocyst burden) on Day [ADDRESS_1133709]-vaccination (animals received two doses of either AGS-v or NRP-V on Days 1 and 15)  Further experiments in C57BL6, BALBc, and CD1 mice have been performed to measure immunogenicity.  All had good responses to the vaccine after two weeks, and  antibodies to AGS-v have been raised to the vaccine many months after vaccination and will likely last multiple years.  T-cell responses are seen two weeks after vaccination, but are harder to predict long-term.  SEEK has performed clinical studies with two other vaccines using the same technology as AGS-v.  Based on their experience with FLU-v and HIV-v in clinical trials it is clear that a combination of four peptides allows the immune system to mount a response without peptides competing with each other.   These studies have also assisted in determination of the appropriate dose as [ADDRESS_1133710] dose which replicated the ratio nmol/Kg in mouse studies, and therefore was the most immunogenic and safe in humans for these other vaccines.  In Phase 1 studies for both HIV-v in HIV-positive males and FLU-v in healthy adults, a dose of 250 ug versus 500 ug with and without adjuvant were given (with approximately 10 people in each arm, for a total of 40 volunteers per Phase 1 study).  In the HIV-v Phase 1 trial, either dose induced a significant and sustained antibody response in 60% of volunteers but only the higher 500 ug dose produced a significant vaccine-specific cellular response in approximately 50% of volunteers.  In FLU-v Phase 1 trial, both adjuvanted doses produced a significant IFN-g response in more than 80% of volunteers in a dose-dependent manner.  A FLU-v Phase II study is evaluating the efficacy of a single dose of adjuvanted 500 ug of FLU-v ([ADDRESS_1133711] received control).  

Universal Mosquito Vaccine Protocol Version 5.[ADDRESS_1133712] Formulation 1 (AGS-v in suspension – lyophilized AGS-v reconstituted in 0.5 mL of water for injection) and contralateral Vehicle Control 1 (water for injection). Erythema resolved by [CONTACT_627762]. There was no edema observed at any test site of administration-related findings on macroscopic evaluation.  In this tolerance study with New Zealand white rabbits, the severity of edema, very slight to slight, and erythema, slight to well-defined, scores was comparable between Test Formulation 2 (AGS-v in emulsion – lysophilized AGS-v reconstituted in 0.25 mL of water for injection and emulsified with 0.25 of Montanide ISA-51) and contralateral Vehicle Control 2 (0.25 mL water for injection and adjuvant, 0.25 mL Montanide ISA-51, emulsion); however a slightly lower incidence associated with evidence of resolution at the end of the observation period was observed for Test Formulation 2. These scores correlated with a lower incidence of macroscopic observations for Test Formulation 2.  Under the conditions of this study, a single subcutaneous injection of AGS-v (Test Formulation 1) caused minimal irritation comparable to contralateral vehicle control with full clinical resolution when administered as a suspension in water and minimal to mild irritation when administered as an emulsion using Montanide ISA-51 (Test Formulation 2) with a slightly lower irritation incidence when compared to contralateral vehicle control.  In summary, the data presented here supports the validity of SEEK’s scientific hypothesis. This states that immunization with mosquito salivary antigens can induce a Th1 specific response that provides both prophylactic and transmission blocking immunity. Equally importantly, and in contrast to other groups that have shown the ability of vaccination with salivary proteins to reduce infection in diseases such as leishmaniasis 26,27.  SEEK’s vaccine is composed entirely of synthetic products that do not require complex heterologous expression systems for manufacture and hence can readily be scaled up to accommodate for large scale demand. The composition and application of these synthetic products are the subject of a patent by [CONTACT_40700].  The AGS-v preparation is a vaccine candidate capable of delivering on both the prophylactic and transmission blocking areas of malaria and arbovirus infection control. 
Universal Mosquito Vaccine Protocol Version 5.[ADDRESS_1133713] 20. This is particularly relevant since many hematophagous arthropods such as Aedes aegypti are responsible for the transmission of more than one pathogen (e.g. dengue, Zika and West Nile virus).    In this protocol we plan to demonstrate the safety of this vaccine similar to SEEK’s other peptide based vaccines Flu-v and HIV-v that have been found to have very good safety profiles in Phase I trials.  We also hope to demonstrate immunomodulation after a controlled clean Aedes aegypti mosquito feeding as proof of concept efficacy of the vaccine.  With the current rise of Zika in the Americas and the threat of it spreading to the U.S. and the rest of the world, a successful universal mosquito-borne disease vaccine offers the benefit of targeting this emerging disease as well as the many established infections such as dengue and malaria that make dealing with this newly emerging epi[INVESTIGATOR_901] a challenge.  2 Study Objectives 2.1 Primary Objective  The primary objectives of the study are: 1. To determine the safety of AGS-v as measured by [CONTACT_818562]  2. To identify an immune response produced by [CONTACT_438137]-v by [CONTACT_818549]: a. Total AGS-v specific immunoglobulin from participant serum [ADDRESS_1133714] and/or second vaccination b. Th1 and Th2-associated cytokine release after incubation of peripheral blood mononuclear cells (PBMCs) collected [ADDRESS_1133715] or second vaccination with AGS-v antigens  2.2 Secondary Objectives The secondary objectives of this study are to identify other measures of immunogenicity including:   1. Measurement of immune response after clean Aedes aegypti mosquito feeding on participants by: a. measuring total AGS-v specific immunoglobulin from serum  b. measuring Th1 and Th2-related cytokines after incubation of PBMCs with AGS-v antigens  
Universal Mosquito Vaccine Protocol Version 5.[ADDRESS_1133716] of incubating Zika virus coated in vector saliva with PBMCs and/or serum collected from vaccinated individuals. 3 Study Design 3.1 Description of the Study Design This is a randomized, double-blind, placebo-controlled, single-center, Phase 1 study of AGS-v administered at Day 0 and Day 21 prior to Aedes aegypti mosquito challenge at Day 42. Subjects will be randomized 1:1:1 to: • Group 1: 825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses • Group 2: 825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses • Group 3: placebo 2 doses   A placebo control will be used to establish the frequency and magnitude of changes in endpoints that may occur in the absence of active vaccination. Randomization will be used to minimize bias in the assignment of participants to vaccination groups, to increase the likelihood that known and unknown participant attributes (e.g., demographic and baseline characteristics) are evenly balanced across vaccination groups, and to enhance the validity of statistical comparisons across vaccination groups. Blinding of participants and the study team will be used to reduce potential bias during data collection and evaluation of endpoints.  3.2 Study Endpoints Primary:  1. Incidence and severity (by [CONTACT_9317]) AEs in AGS-v vaccinated individuals 2. Total AGS-v specific immunoglobulin measured in serum [ADDRESS_1133717] and/or second vaccination. 3. Interferon-gamma and other cytokine markers of Th1 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of the expected Th1 response  Secondary:  
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 23 of 62  1. Total AGS-v specific immunoglobulin in acute serum collected immediately after a clean Aedes aegypti mosquito feeding and convalescent serum collected on follow-up visits (60 days later +/- 14 days)               2. Interferon-gamma and other cytokine markers of a Th1 or Th1/Th2 mixed response measured in vitro from acute PBMCs and serum collected immediately after a clean Aedes aegypti mosquito feeding incubated with AGS-v antigens and convalescent PBMCs and serum collected on follow-up visits (60 days later +/- 14 days) 3. Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination both in vivo and in vitro, including survival, egg laying, and other measures of reproduction. 4. Infectivity of Zika virus after incubation with serum and/or PBMCs from vaccinated participants  [ADDRESS_1133718] the optimum participants for completing the study objectives and minimize the risk of AEs. NIH employees and members of their immediate families may participate in this protocol. We will follow the Guidelines for the Inclusion of Employees in NIH Research Studies and will give each employee a copy of the “NIH information sheet on Employee Research Participation.”   For NIH employees:  • Neither participation nor refusal to participate will have an effect, either beneficial or adverse, on the participant’s employment or work situation.  • The NIH information sheet regarding NIH employee research participation will be distributed to all potential subjects who are NIH employees.  • The employee subject’s privacy and confidentiality will be preserved in accordance with NIH Clinical Center and NIAID policies, which define the scope and limitations of the protections.  • For NIH employee subjects, consent will be obtained by [CONTACT_591155]’s team. Those in supervisory position to any employee and co-workers of the employee will not obtain consent.  
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 24 of 62 • The importance of maintaining confidentiality when obtaining potentially sensitive and private information from co-workers or subordinates will be reviewed with the study staff at least annually and more often if warranted.    4.2 Recruitment Plan Participants will be recruited through the screening study #11-I-0183 “Screening of Volunteers for Influenza Human Challenge and Vaccine Studies”. Participants will be carefully screened and evaluated, and those who meet the study eligibility criteria will be contact[CONTACT_818563]. A staggered enrollment procedure will be followed with the initial enrollment phase to include [ADDRESS_1133719] cohort.  These will be block randomized so that 2 receive placebo, 2 vaccine, and 2 vaccine plus adjuvant.  If no pausing or halting criteria are met per the safety evaluations described in Section 12 Assessment of Safety for these initial 6 patients one week after the second vaccine administration (~Day 28), the following cohort will include 9 patients.  Then, if no pausing or halting criteria or safety concerns arise by [CONTACT_818564] (~Day 28),  the remaining 30 patients will be enrolled in appropriately sized cohorts with 15 patients in each arm to complete the study efficiently.  If a participant has completed the screening study #11-I-0183 more than 60 days prior to Day 0 of this study, they will be asked to come to the NIH Clinical Center for another screening visit under the screening study #11-I-0183 within 60 days prior to the date of vaccination to repeat HIV testing and complete any laboratory or other testing as deemed necessary by [CONTACT_818565].  All eligible participants will be consented and enrolled for this study only after completion of all necessary screening studies under protocol #11-I-[ADDRESS_1133720] prior to Day 0 (Day of vaccine/placebo administration).   4.3 Inclusion Criteria 1. Healthy women and men who are ≥18 and ≤[ADDRESS_1133721] is eligible for the study if he agrees to practicing abstinence or using a condom with spermicide plus an acceptable form of contraception (see inclusion criteria 4) being used by [CONTACT_40708] [ADDRESS_1133722] feeding and 1 of the following: 
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 25 of 62 • Of non-child bearing potential (i.e., women who have had a hysterectomy or tubal ligation or are postmenopausal, as defined by [CONTACT_40709] ≥1 year). • Of childbearing potential but agrees to practice effective contraception or abstinence for 4 weeks prior to study initiation through 12 weeks after the second vaccine administration. Acceptable methods of contraception include a male partner who is sterile and is the sole sexual partner of the female participant or a male partner who uses a condom with spermicide plus 1 or more of the following: 1) implants of levonorgestrel; 2) injectable progestogen; 3) an intrauterine device with a documented failure rate of <1%; 4) oral contraceptives; and 5) double barrier method including diaphragm. 5. Willing to have samples stored for future research (including genetic research). 6. Agrees to abstain from alcohol intake for 24 hours prior to each study visit. 7. Agrees to not donate blood or blood products throughout the study.  4.4 Exclusion Criteria  1. Participant has any underlying or current medical condition, which, in the opi[INVESTIGATOR_689], would interfere with the participation in the study.  2. Individual with body mass index (BMI) £18 and ≥40.  3. Participants who have a clinically significant (as determined by [CONTACT_978]) baseline Grade 1 or greater toxicity, or any Grade 3 or greater toxicity (regardless of clinical significance) by [CONTACT_79833].   4. Receipt of blood or blood products (including immunoglobulins) within 3 months prior to enrollment. 5. Receipt of any unlicensed drug within 3 months or 5.5 half-lives (whichever is greater) prior to enrollment. 6. Receipt of any unlicensed vaccine within 6 months prior to enrollment. 7. Self-reported or known history of alcoholism or drug abuse within 6 months prior to enrollment, or positive urine/serum test for drugs of abuse at screening  8. Self-reported or known history of psychiatric or psychological issues that require treatment and are deemed by [CONTACT_978] [INVESTIGATOR_79796] a contraindication to protocol participation.  9. History of a previous severe allergic reaction with generalized urticaria, angioedema, anaphylaxis or anaphylactoid reaction. 10. Any condition or event that, in the judgment of the PI, is a contraindication to protocol participation or impairs the volunteer’s ability to give informed consent. 11. Has a known allergy to any of the components of the vaccine. 
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 26 of 62 12. Has a history of severe immunization reaction. 13. Has a severe allergic reaction to mosquito bites  Co-enrollment Guidelines: Co-enrollment in other trials is restricted, but may take place with the approval of the PI [INVESTIGATOR_40634]. 4.5 Justification for Exclusion of Pregnant Women and Children (Special Populations) In this study, an investigational vaccine will be administered to the participants. Therefore, children, pregnant women, and individuals at high risk of complications will be excluded as the risk to these individuals may be increased. In addition, the investigational vaccine has not undergone reproductive safety tests.  Participants younger than 18 years of age will be excluded from the study. Because there are insufficient data regarding dosing or AEs available in adults to judge the potential risk in children, the study is of “greater than minimal risk” and does not meet the criterion of 45 Code of Federal Regulations (CFR) 46, Subpart D, governing the participation of children in research. 5 Study Agents/Interventions  5.1 Agent 1: AGS-v, AGS-v + Adjuvant, or Placebo 5.1.1 Formulation, Packaging and Labeling AGS-v contains four drug substances: AGS-6, AGS-30, AGS-31, and AGS-35.  These are peptides consisting of 32 to 44 amino acids.  They are obtained by [CONTACT_818566].  The peptides contain multiple T-cell reactive regions capable of inducing Th1 responses.  A solution of the four drug substances (50 nmol net peptide/g of each drug substance) is prepared by [CONTACT_818567] (WFI).  The four solubilized peptides are mixed to make up AGS-v solution.  This mix is filter-sterilized before filling glass vials automatically with the sterile AGS-v solution.  The pharmaceutical formulation solution is filled into glass vials by [CONTACT_40713] 0.824g of AGS-v solution per vial which is then lyophilized before closing with a rubber stopper and a flip-off cap.  The lyophilization removes both the water component; whereupon a relatively neutral pH, suitable for human injection, is achieved by [CONTACT_818568].  Bottle labels will bear the appropriate label text as required by [CONTACT_9071].  Any addition or modification to the label apart from the variable data must be authorized by [CONTACT_86962]. 
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 27 of 62 5.1.2 Study Agent Storage and Stability The vials of WFI and Montanide ISA-51 should be stored at room temperature.  Stability will be performed to cover the duration of the trial.  Stability studies of previous batches of another vaccine Flu-v indicate that it should remain stable for 2 years when stored at -15 to -25°C which should be the case for the AGS-v vaccine also.  None of the materials can be dispensed beyond the expi[INVESTIGATOR_320].  5.1.3 Adjuvant The adjuvant is Montanide ISA 51, also known as incomplete Freund’s adjuvant (IFA).  This is a mixture of oil and water that when combined with an antigen (such as a vaccine) it boosts the response to that antigen.  It is comprised of two raw materials Drakeol 6 VR as a mineral oil and mannide monooleate as the surfactant.28     Drakeol 6 VR is a mineral oil with USP/EP monograph. It is a mixture of several hydrocarbons with different length obtained from petroleum. Drakeol 6 VR stays at the injection site and is progressively eliminated by [CONTACT_818569]. It can also be partially metabolized into fatty acids, triglycerides, phospholipi[INVESTIGATOR_805], or sterols. 30% of the mineral oil disappears during the first month and the majority of the oil found outside the injection site is in the liver and fatty tissues in the form of phospholipi[INVESTIGATOR_40635].28  Mannide monooleate is a non ionic surfactant based on oleic acid and sugar. Oleic acid is a distribution of various fatty acids with a predominant species C18'.  30-40% of mannide monooleate is removed from the injection site after 24 hours. After 3 months, 30% of the surfactant still remains.[ADDRESS_1133723] used as placebo.  5.1.5 Preparation • Please see Pharmacy Manual Section 2.3. • Two members of the study staff, [CONTACT_818582] (associate investigator) and Lindsay Czajkowski (NP), will perform emulsification and blinding of all syringes and accountability for the AGS-v study agent.  Therefore, these two 
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 28 of 62 members of the study staff will be unblinded and will not participate in any other aspects of the study or patient care. • Once prepared and drawn into the syringe, it should be administered within 3 hours. • Once emulsification of the adjuvant and vaccine occurs, it should be administered within 15 minutes.  5.2 Dosing and Administration  Subjects will be randomized to one of the following vaccination regimens:  • Group 1: AGS-v (unadjuvanted) as a suspension in WFI (0.5 mL) on Day 0 and on Day 21 • Group 2: ISA-51-adjuvanted AGS-v emulsified in WFI (0.5 mL) on Day 0 and on Day 21 • Group 3: WFI (0.5 mL) on Day 0 and Day 21  All doses administered by [CONTACT_40719].  The person administering the vaccine will be blinded to the type of formulation (adjuvanted or not adjuvanted) because an opaque label will be placed over the syringe by [CONTACT_1714].  The NIH Special Clinical Studies Unit (SCSU) or other appropriate clinical unit nurses will administer the vaccines.  No member of the study team will be administering the blinded study product.  Administration of the vaccine will be performed following these instructions as detailed in the NIH Clinical Center subcutaneous vaccine administration guidelines29:  To locate the injection site on the arms, fold one arm across the chest.  Place your hand on the shoulder and draw an imaginary line below your hand.  Place another hand on the elbow.  Draw an imaginary line down the outer side of the arm and down the center front of the arm, starting at the elbow.  The area inside these imaginary lines is where injections are given.   Cleanse the area of the skin thoroughly before a needle is inserted.  Cleanse the skin with a back and forth motion using an alcohol swab.  This motion moves bacteria away from the injection site.  Allow the alcohol to dry completely by [CONTACT_94269].   • Take the cover off the needle.  Be careful not to contaminate the needle.  Place the cover on its side. Hold the syringe in one hand like pencil or a dart.  Grasp the skin between the thumb and index finger with your other hand and pi[INVESTIGATOR_368343].  • Quickly thrust the needle all the way into the skin.  Do not “push” the needle into the skin slowly or thrust the needle into the skin with great 
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 29 of 62 force.  Do not press down on the top of the plunger while pi[INVESTIGATOR_818535].  • Insert the needle at a 90° (right) angle.  This angle is important to ensure that the medications will be injected into the fatty tissue.  However, for persons with little subcutaneous fat on thin skin, you may be taught to use a 45° angle.  • After the needle is completely inserted into the skin, release the skin that you are graspi[INVESTIGATOR_007].  Press down on the plunger to release medication into the subcutaneous layer in a slow, steady pace. Count 10 seconds before removing the needle from the skin.  • As the needle is pulled out of the skin, gently press a gauze pad onto the needle insertion site. Pressure over the site while removing the needle prevents skin from pulling back, which may be uncomfortable.  The gauze also helps seal the punctured tissue and prevents leakage.   It is not serious if you notice blood at the site after the needle is removed.  You may have nicked a surface blood vessel when you injected, and blood is following the needle track out to the surface.  Simply press the site with a [ADDRESS_1133724] identification, quantity (volume) and date of administration.  The containers from which the vaccine was administered to the subjects will be retained for dose confirmation.  At the end of the study, delivery records of study vaccine will be reconciled with used / unused stocks and appropriate forms will be completed, to verify that all used, unused or partially used supplies have been returned and that no study supplies remain in the Investigator’s possession.  All unused vaccine supplies, partially used and empty containers will be returned to the drug supplier. 
Universal Mosquito Vaccine Protocol Version 5.[ADDRESS_1133725] (IP) accountability, reconciliation and record maintenance.  In accordance with all applicable regulatory requirements, the investigator or designated site staff must maintain investigational product accountability records throughout the course of the study.  The investigator or designated site staff will document the amount of investigational product received from SEEK and the amount administered to subjects.  A Drug Dispensing Log must be kept current and will contain the following information:  • The identification of the subject to whom the drug was dispensed. • The date(s) of the drug dispensed to the subject.  The inventory must be available for inspection by [CONTACT_40721].  Drug supplies, excluding empty containers, will either be collected at the end of the study by [CONTACT_818570].  When requested in writing by [CONTACT_86962], unused drug supplies may be destroyed by [CONTACT_818571].  Records will be maintained by [CONTACT_818572].  These records must show the identification and quantity of each unit disposed of, the method of destruction (taking into account the requirements of local law), and the person who disposed of the test substance.  Such records must be submitted to the drug supplier.  5.3.[ADDRESS_1133726] be approved by [CONTACT_978] [INVESTIGATOR_818536]’s source documents. For this protocol, a prescription medication is defined as a medication that can be prescribed only by a properly authorized/licensed clinician.  [ADDRESS_1133727] completed the study and the database is finalized. Otherwise, the blind should be broken only if specific emergency treatment/course of action would be dictated by [CONTACT_40704]. In such cases, the investigator may in an emergency determine the identity of the vaccine by [CONTACT_413435]. It is recommended that the investigator contact [CONTACT_97499], before breaking the blind. In the event the blind is broken, the sponsor must be informed as soon as possible. Accidental unblinding (e.g. if the Investigator sees the IP administration logs) must be reported within [ADDRESS_1133728] (DSMB).   6.2 Randomization and Vaccine or Placebo Administration (Day 0)  The first vaccine or placebo administration will take place on Day 0. This visit will occur in the SCSU or other appropriate CC unit/clinic. The research team will thoroughly discuss the consent with the volunteer prior to performing any and all procedures. Once it is determined that the participant still meets inclusion/exclusion criteria for the research study, participants will receive the first of two injections of AGS-v +adjuvant 0.5 mL dose, AGS-v 0.5 mL dose, or placebo.  All participants will be educated by [CONTACT_818573], but not limited to, minimizing skin exposure with long sleeves/pants and the use of repellent.   

Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 32 of 62  The following procedures will be performed after informed consent is obtained:  • Review of medical/medication history • Documentation of usual responses to mosquito bites as none (0), mild (1), moderate (2), or severe (3) • Physician exam/assessment  • Vital signs including weight pre vaccination • Vital signs (+/- 15 minutes) post vaccination at 30 minutes, 60 minutes, and 120 minutes • Blood collection for routine safety labs (as per Appendix A), total serum IgE,  as well as serum/whole blood for research (as per Appendix B). • Routine urinalysis • Serum pregnancy test (females only) • Review of inclusion/exclusion criteria  • Vaccine or placebo administration  • Required 2 (two) hour observation time (post vaccine injection) at the clinical research site • Vaccine injection site and AE assessment pre-vaccination, [ADDRESS_1133729] vaccination (+/- 15 minutes) • Any other clinical tests that are medically indicated or appropriate to ensure the safety of the individual participant as deemed by [CONTACT_978] • Diary card, thermometer, and ruler will be distributed prior to discharge home  6.3 Day 7 (+/- 2 days) • Clinic visit • Review of medical/medication history • Physician exam/assessment • Vital signs including weight • Blood collection for routine safety labs • Routine urinalysis • Serum pregnancy test (females only) • Vaccine injection site assessment  • Review of diary card 6.4 Day 14 (+/- 2 days) • Clinic visit • Review of medical/medication history • Physician exam/assessment • Vital signs including weight • Blood collection for routine safety labs 
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 33 of 62 • Routine urinalysis • Serum pregnancy test (females only) • Vaccine injection site assessment  6.5 Day 21 (+/- 2 days) This visit will take place in the SCSU or other appropriate CC unit/clinic.  The second study vaccine administration will take place if the participant continues to meet all inclusion and none of the exclusion criteria following these procedures:  • Review of medical/medication history • Physician exam/assessment • Vital signs and including weight • Vital signs (+/- 15 minutes) post vaccination at 30 minutes, 60 minutes, and 120 minutes • Blood collection for routine safety labs as well as serum/whole blood for research  • Routine urinalysis • Serum pregnancy test (females only) • Vaccine or placebo administration  • Required 2 (two) hour observation time (post vaccine injection) at the clinical research site • Vaccine injection site and AE assessment pre-vaccination, [ADDRESS_1133730] vaccination (+/- 15 minutes) • Any other clinical tests that are medically indicated or appropriate to ensure the safety of safety the individual participant as deemed by [CONTACT_978] • Diary card, thermometer, and ruler will be distributed prior to discharge home 6.6 Day 28 (+/- 2 days) • Clinic visit • Review of medical/medication history • Physician exam/assessment • Vital signs including weight • Blood collection for routine safety labs • Routine urinalysis • Serum pregnancy test (females only) • Vaccine injection site assessment  • Review of diary card 6.7 Day 35 (+/- 2 Days) • Clinic visit • Review of medical/medication history • Physician exam/assessment 
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 34 of 62 • Vital signs including weight • Blood collection for routine safety labs • Routine urinalysis • Serum pregnancy test (females only) • Vaccine injection site assessment  6.8 Day 42 Mosquito Feeding (+14 days) This will take place in the SCSU or other appropriate CC unit.  The following procedures/assessments and testing will be performed: • Review of medical/medication history and addition of any new information • Physician assessment and physical exam • Vital signs including weight • Routine urinalysis • Placement of IV catheter in arm • Serum pregnancy test (females only) • Blood collection for routine safety labs and serum/whole blood for research prior to mosquito feeding. • Per Appendix B: serum 8 ml tube x 1, whole blood 8.5 ml tube x 10, and Paxgene 2.5 ml x1 • Mosquito feeding: • Starved female Aedes aegypti mosquitos will be selected from a mosquito colony approved for human feeding studies in Laboratory of Malaria and Vector Research (LMVR), NIAID.  5 -10 female mosquitoes will be secured in the feeding device prior to feeding and brought to the CC from the LMVR Insectary.  • The feeding site will be wiped clean with mild unscented soap and water and the device will be placed on the participant’s arm for 20 minutes.  The mosquitos will feed through a disposable mesh on the bottom of the feeding device..  In the unlikely event of no feeding or poor feeding (only 0-2 mosquitoes fed or probed as noted by [CONTACT_32341]), the volunteer may undergo a repeat feed with 5-10 fresh mosquitoes ONCE.   • Participants will be asked not to apply cream, perfume or deodorant the day of mosquito exposure. Once the mosquitos have fed they will remain in the same device and be brought back to the lab for further study. • The skin will be inspected pre-feeding.  Redness, swelling and number of visible bites will be recorded pre-feeding, immediately post feeding and [ADDRESS_1133731] feeding (+/- 15 minutes) • Research blood collection (+/- 15 minutes) after mosquito feeding will be collected at: • 30 minutes: whole blood (8.5 mL tubes x 5), serum (8 ml tube x 1), and 2.5 mL in Paxgene tube • 60 minutes: 2.5 mL for Paxgene tube • 120 minutes: 2.5 mL Paxgene tube 
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 35 of 62 • 180 minutes: whole blood (8.5 mL tubes x 5), serum (8 ml tube x 1), and 2.5 mL in Paxgene tube • Any other clinical tests that are medically indicated or appropriate to assure the safety of the individual participant as deemed by [CONTACT_978]. • AE assessment  6.9 Day 44 Telephone Call (+/- 1 day) A brief telephone call will be made on Study Day [ADDRESS_1133732] in the clinic approximately every 60 days (±14 days) for the next 5 months or more often if deemed medically necessary; the procedures/evaluations to be conducted at these visits are shown in Appendix A. The 10-month post Day 42 visit will be the final study visit unless the participant requires additional follow-up of study-related complications.   7 Study Procedures/ Evaluations 7.1 Clinical and Laboratory Evaluations See Appendix A for clinical and laboratory procedures performed during the vaccination and mosquito feeding visits as well as follow-up portions of the study. See Appendix B for Blood Volumes for Specimen Collection. Many of these tests are being performed to monitor safety and ensure that participants are healthy enough to undergo vaccination and mosquito feeding. 7.1.1 Laboratory Testing of Collected Samples for Primary and Secondary Endpoints • Primary Endpoints: o AGS-v specific immunoglobulin assay will be performed using enzyme-linked immunosorbent assay (ELISA). o Th1 and Th2 response assays: PBMCs collected from participants will be incubated with AGS-v and measurements of various Th1 and Th2 cytokines will be performed using Luminex and/or ELISA • Secondary Endpoints: 
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 36 of 62 o AGS-v specific immunoglobulin and interferon-gamma assay will be performed as stated above on samples collected after Aedes aegypti mosquito feeding occurs.   o Specific IgG subclasses will be measured using ELISA o Mosquito Studies:  § Feeding on human volunteers: [ADDRESS_1133733] only been sugar-fed up until now. Female mosquitoes will be placed in a secured Plexiglass feeding device and allowed to feed on the volunteer’s arms on Day 42 (approximately [ADDRESS_1133734] completed the vaccination schedule).  Mosquitoes that had a blood meal will then be removed and followed up to assess any changes to their life cycle, i.e., life-span, number of eggs laid, number of fertile eggs, number of surviving larvae etc.  The mosquito colony used in this study will not be fed on human blood but on non-mammalian blood to minimize the presence of blood borne pathogens in them. o Zika virus killing, in vitro toxicity assay:  § Blood samples will be obtained from all volunteers 21 days after vaccination is completed. PBMCs+sera containing immune cells and antibodies generated against AGS-v will be tested for their ability to kill Zika virus mixed with salivary gland proteins from Aedes aegypti. This test will be carried out in 96 well plates.   § Salivary gland proteins will be obtained after dissecting the salivary glands from female Aedes aegypti, sonicating them and centrifuging the sonicate to obtain the supernatant containing all the mosquito salivary proteins.   § Zika virus will be obtained from a commercial supplier (ATCC® VR-1838). This strain can be propagated in vitro by [CONTACT_818574]. Cells are plated 18-24 hours prior to infection and infected when cultures are 75-80% confluent. The medium is removed, cell monolayer is washed with PBS or serum free medium prior to inoculation with a small volume of inoculum (e.g. 1 mL per 25 cm2) diluted to provide an optimal MOI (e.g. 0.1-0.01). The inoculum is left to adsorb for 1-2 hours at 37°C in a humidified 5% CO2 atmosphere. End adsorption by [CONTACT_818575]. Cells are incubated for 2-4 days at 37°C in a humidified 5% CO2 atmosphere, until cytopathic effect is progressed through 80-90% of the monolayer. At this point the propagated virus is collected.   § In order to assess that the AGS-v specific immune responses have killed the Zika virus, the PBMC+Zika+salivary protein cultures will be spun to remove any cells. Any viable Zika virus will be found in the 
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 37 of 62 supernatant which will be used to attempt re-infection of VERO cells and/or PCR. If infection is not successful and/or PCR is negative it will be an indication that the virus was destroyed.  7.[ADDRESS_1133735] temperature, any local (redness, swelling, and pain) or general symptoms (e.g., fever, chills, headache, myalgia, arthralgia, sweats, fatigue, nausea, vomiting) they experience on the diary card.  The diary card will be brought to each clinic visit.  The diary cards will be reviewed and evaluated for AEs.    The diary card will be completed by [CONTACT_818576].  Subjects will be instructed on the use and bring it to every clinic visit.  The diary card will be reviewed by [CONTACT_818577].  Diary cards will be collected from subjects, and retained as source documentation.  If diary cards are not completed or returned, the study team will review the AEs that occurred during that timeframe to the best of the subject’s recollection.    8 Potential Risks and Benefits 8.1 Risks of Placebo administration Subcutaneous injection of water for injection (WFI) poses minimal risk.  The primary risks of the placebo vaccinations are a local vaccine reaction or infection at the site of injection.  Signs of a local vaccine reaction include pain, swelling, and redness at the site of injection.  These reactions resolve after short period of time and pose little risk to the participant.  Applying cold packs and administering over the counter pain medications if necessary can generally treat these reactions.  Signs of infection include pain, redness, swelling, edema, and drainage at the site. 8.2 Risks of AGS-v ± adjuvant vaccination Vaccine reactions must be considered a risk of all vaccines.  These include minor and severe vaccine reactions.  A minor vaccine reaction typi[INVESTIGATOR_40645] a few hours of injection and resolve within a short period of time posing little risk to the participant.  Symptoms include local pain, swelling, and redness at the site of injection and may include systemic symptoms like fever, malaise, muscle pain, headache, and loss of appetite.  Severe reactions usually do not result in long-term problems for the participant, but can be disabling.  They are rarely life threatening, but can be.  These reactions can include severe anaphylactic reactions and seizure.  Primarily topi[INVESTIGATOR_818537], topi[INVESTIGATOR_818538].  Additional standard of care therapy for pain or anaphylaxis will be administered if the reaction becomes 
Universal Mosquito Vaccine Protocol Version 5.[ADDRESS_1133736] been observed in any participants receiving either of these vaccines.  Safety results from the FLU-v and HIV-v studies are presented below and no safety concerns were identified during those Phase I trials.  In the Phase 1a Study Flu-v-001, no deaths occurred and only 1 SAE was reported with this being considered unrelated to FLU-v (appendicitis).  There was no apparent increase in AEs with a change in dose from the 250 μg or 500 μg (500 µg of FLU-v is the equivalent of 825 µg of AGS-v as both contain 50 nmol of each peptide), but an approximate 2-fold increase in AEs was seen in the adjuvant versus non-adjuvant groups. This latter point is likely responsible for the largely local administration site reaction AEs; however, the forearm site and [ADDRESS_1133737] also been documented in vaccines adjuvanted with Montanide ISA-5130-34, but these were not observed in the FLU-v trials of healthy volunteers.  In the Phase 1b Study Flu-v-002, all 32 subjects reported AEs: 32 mild, 10 moderate and one severe (a pre-syncopal epi[INVESTIGATOR_40647]).  There were no deaths or SAEs.  The most frequently reported AEs were related to the injection site reactogenicity and are consistent with those already documented with use of the Montanide ISA-51 adjuvant. There were no other clinically significant changes in the other safety parameters (complete physical examination, clinical chemistry, hematology and urinalysis, vital signs including oral temperature, ECG).  In the Phase 1b Study HIV-v-[ADDRESS_1133738] commonly reported AEs.  The majority of AEs were of mild severity (69.7%).  There were [ADDRESS_1133739] (lower abdominal pain, shigella infection, and gastroenteritis) 37 days prior to vaccination, 31 and 128 days after vaccination respectively.  The other 2 SAEs (perianal abscess with streptoccacl infection and Kaposi’s sarcoma) occurred at [ADDRESS_1133740] of immune-mediated conditions that will be monitored.  Gastrointestinal disorders - Celiac disease - Crohn’s idseas - Ulcerative colitis and proctitis  Liver disorders - Autoimmune cholangitis - Autoimmune hepatitis - Primary biliary cirrhosis  - Primary sclerosing cholangitis  Metabolic diseases - Addison’s disease - Autoimmune thyroiditis - Diabetes mellitus type [ADDRESS_1133741]’s disease  Musculoskeletal disorders  - Antisynthetase syndrome - Dermatomyositis - Juvenile chronic arthritis - MCTD - Polymyalgia rheumatica - Polymyositis - Psoriatic arthropathy - Relapsing polychondritis - Rheumatoid arthritis - Sclerderma (including CREST And systemic diffuse form) - Spondyloarthritis - Systemic lupus erthematosus - Systemic sclerosis  Neuroinflammatory disorders 
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 40 of 62 - Acute disseminated encephalomyelitis - Cranial nerve disorders - Guillain Barré syndrome - Immune-mediated peripheral neuropathies and plexopathies - Multiple sclerosis - Narcolepsy - Optic neuritis - Transverse myelitis - Myasthenia gravis  Skin disorders - Alopecia areata - Autoimmune bullous skin disease such as pemphigus, pemphigoid, and dermatitis herpetiformis - Cutaneous lupus erythematosus - Erythema nodosum - Morphoea - Lichen planus - Psoriasis - Sweet’s syndrome - Vitiligo  Vasculitides - Large vessel vasculitides such as giant cell arteritis and Takayasu’s arteritis and temporal arteritis - Medium and small sized vessels: polyarteritis nodosa, Kawasaki’s, miscrosocpic polyangiitis, Wegener’s granulomatosis, Churg-Staruss, Buerger’s, Henoch Schonlein purpeura and Behcet’s  Others - Antiphospholipid syndrome - Autoimmune hemolytic anemia - Autoimmune glomerular nephritis - Autoimmune myocarditis/cardiomyopathy - Autoimmune thrombocytopenia - Goodpasture syndrome - Idiopathic pulmonary fibrosis - Pernicious anemia  - Raynaud’s phenomenon - Sarcoidosis - Sjogrens’ syndrome - Steven-Johnson syndrome - Uveitis   8.4 Risks of blood draw Risks of blood draw include pain, bruising, bleeding, and rarely fainting or infection.  The amount of blood drawn will be within the limits allowed for adult subjects by [CONTACT_818578] 5.0 09 Feb, 2018  
Page 41 of 62 Clinical Center (Medical Administrative Policy 95-9: Guidelines for Limits of Blood Drawn for Research Purposes in the Clinical Center:  http://cc-internal.cc.nih.gov/policies/PDF/M95-9.pdf).  Exceptions to this limit will be submitted to the Institutional Review Board (IRB) for prior approval. 8.[ADDRESS_1133742] benefit to the participant.  The information collected from this study will allow a better understanding of the safety and immunogenicity of AGS-v and may inform further development of this or other universal mosquito-borne disease vaccines. 9 Research Use of Stored Human Samples, Specimens, or Data Intended Use: Samples and data collected under this protocol may be used to study aspects of Zika virus infection and other mosquito-borne diseases. Genetic testing will not be performed. A separate signed informed consent document will be obtained for any other research not described in this protocol. Storage: Access to stored samples will be limited using a locked freezer in a locked laboratory. Samples and data will be stored using codes assigned by [CONTACT_473]. Data will be kept in password-protected computers. Only investigators will have access to the samples and data.  Tracking: Samples will initially be stored in laboratories of primary and associate investigators. Samples will be tracked using a database located on password-protected computers, which will be maintained by [CONTACT_40735]. Only investigators and their designees will have access to this database.  Disposition at the Completion of the Protocol:  • In the future, other investigators (both at NIH and outside) may wish to study these samples and/or data. In that case, IRB approval must be sought prior to any sharing of samples and/or data. Any clinical information shared about the samples would similarly require prior IRB approval.  • At the completion of the protocol (termination), samples and data will either be destroyed, or after IRB approval, transferred to another existing protocol. Reporting the Loss or Destruction of Samples/Specimens/Data to the IRB: • Any loss or unanticipated destruction of samples or data (for example, due to freezer malfunction) that meets the definition of protocol deviation and/or compromises the scientific integrity of the data collected for the study will be 
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 42 of 62 reported to the IRB. The PI [INVESTIGATOR_818539]. • Additionally, subjects may decide at any point not to have their samples stored. In this case, the principal investigator [INVESTIGATOR_818540]. This decision will not affect the subject’s participation in this protocol or any other protocols at NIH. 10 Data Sharing Plan 10.1 Human data generated in this study will be shared for future research as follows: • De-identified data in an NIH-funded or approved public repository. • Identified data in BTRIS. • De-identified or identified data with approved outside collaborators under appropriate agreements. 10.2 Data will be shared through: • An NIH-funded or approved public repository. Insert name(s): ClinicalTrials.gov____ • BTRIS. • Approved outside collaborators under appropriate individual agreements. • Publication and/or public presentations. 10.3 The data will be shared: • At the time of publication or shortly thereafter.  11 Remuneration Plan  Participants will be compensated according to Table 1. Participant remuneration .    Table 1. Participant remuneration  Day 0  $200 Day 7 (± 2 days) $70 Day 14 (± 2 days) $70 Day 21 (± 2 days) $200 Day 28 (± 2 days) $80 Day 35 (± 2 days) $80 Day 42 (+ 14 days) $400     Follow up visits ~60 days (± 14 days) X5  $60 x 5=$300   
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 43 of 62 Expected total for completion of ALL study visits $1,400    Study-requested interim visits: $[ADDRESS_1133743] with the participant, information regarding AEs will be elicited by [CONTACT_4524]:  • Immediately documented in the participant’s medical record/source document, • Recorded in CRIMSON • Reported as outlined below (e.g., IND Sponsor, IRB, FDA). If a diagnosis is clinically evident (or subsequently determined), the diagnosis rather than the individual signs and symptoms or lab abnormalities will be recorded as the AE.  All abnormal laboratory findings will be reviewed on a routine basis by [CONTACT_458] [INVESTIGATOR_700604]. An abnormal lab not included on the toxicity table should be assessed in a similar fashion to the criteria above. 12.[ADDRESS_1133744], including any abnormal sign (for example, abnormal physical exam, or laboratory finding), symptom, or disease, temporally associated with the subject’s participation in the research, whether or not considered related to the research.   Adverse Reaction (AR) An AE that is caused by [CONTACT_4523] (drug or biologic).  Suspected AR (SAR) An AE for which there is a reasonable possibility that the investigational agent caused the AE. ‘Reasonable possibility’ means that there is evidence to suggest a causal relationship between the drug and the AE. An SAR implies a lesser degree of certainty about causality than AR, which implies a high degree of certainty. 
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 44 of 62  Serious Adverse Event (SAE) An SAE is an AE that results in 1 or more of the following outcomes: • Death • A life-threatening event (places the subject at immediate risk of death from the event as it occurred) • An inpatient hospi[INVESTIGATOR_1324] • A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions  • A congenital anomaly/birth defect • A medically important event* *Medical and scientific judgment should be exercised in deciding whether expedited reporting is appropriate in other situations, such as important medical events that may not be immediately life threatening or result in death or hospi[INVESTIGATOR_818541].  Unexpected Adverse Event: An AE is unexpected if it is not listed in the Investigator’s Brochure or Package Insert (for marketed products) or is not listed at the specificity or severity that has been observed. It is the responsibility of the IND sponsor to make this determination.  Serious and Unexpected SAR (S[LOCATION_003]R) A S[LOCATION_003]R is an SAR that is both serious and unexpected.  Unanticipated Problem (UP) A UP is any event, incident, experience, or outcome that is 1. Unexpected in terms of nature, severity, or frequency in relation to a. The research risks that are described in the IRB-approved research protocol and informed consent document, Investigator’s Brochure, or other study documents; and b. The characteristics of the participant population being studied; and 2. Possibly, probably, or definitely related to participation in the research; and 3. Places participants or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized. (Per the IND Sponsor, an AE with a serious outcome will be considered increased risk.)  UP that is not an AE (UPnonAE)  A UP that does not fit the definition of an AE, but which may, in the opi[INVESTIGATOR_871], involve risk to the subject, affect others in the research study, or significantly impact the integrity of research data. Such events would be considered a 
Universal Mosquito Vaccine Protocol Version 5.[ADDRESS_1133745] to seriousness (criteria listed above), severity (intensity or grade), and causality (relationship to study agent and relationship to research) according to the following guidelines.   12.3.1 Severity The investigator will grade the severity of each AE according to the FDA “Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials” September 2007, which can be found at: http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074775.htm    Microscopic hematuria will be graded using the above toxicity table except for the Grade 1 values, which are being adjusted to be consistent with the CC Department of Laboratory Medicine normal laboratory values.  Grade 1 will be >3-10 RBC/HPF instead of 1-10 RBC/HPF listed in the FDA toxicity table.  All lab and vital sign abnormalities found prior to administration of the vaccine or placebo will be documented as a baseline AE and will be assessed for clinical significance and the participant will be reassessed for inclusion or exclusion to receive vaccination.  After administration of vaccine or placebo, all new gradable abnormalities not found at baseline will be reported as AEs.    Severity grading for clinical events that are not found in the FDA Healthy Volunteer Toxicity Table will be graded according to the following grading scale:  • Grade 1 (Mild)  Events causing no or minimal interference with daily activity • Grade 2 (Moderate)  Events causing greater than minimal interference with daily activity but not requiring medical intervention • Grade 3 (Severe)  Events causing inability to perform daily activity and/or requiring medical intervention • Grade 4 (Potentially Life-Threatening)*  Events causing inability to perform basic self-care functions OR medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death  
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 46 of 62 *Note: A severity assessment of “potentially life-threatening” is not necessarily the same as life-threatening as an "SAE" criterion. The latter means that the event is an immediate threat to life as opposed to a potential threat to life. 12.3.2 Causality Causality (likelihood that the event is caused by [CONTACT_4526]) will be assessed considering the factors listed under the following categories:  Definitely Related • Reasonable temporal relationship • Follows a known response pattern • Clear evidence to suggest a causal relationship • There is no alternative etiology  Probably Related • Reasonable temporal relationship • Follows a suspected response pattern (based on similar products) • No evidence of a more likely alternative etiology  Possibly Related • Reasonable temporal relationship • Little evidence for a more likely alternative etiology  Unlikely Related • Does not have a reasonable temporal relationship  OR • Good evidence for a more likely alternative etiology  Not Related • Does not have a temporal relationship  OR • Definitely due to an alternative etiology  Note: Other factors should also be considered for each causality category when appropriate. Causality assessment is based on available information at the time of the assessment of the AE. The investigator may revise the causality assessment as additional information becomes available. 
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 47 of 62 12.4 Investigator Reporting Responsibilities to the Sponsor  12.4.1 AEs AE data will be submitted to the IND sponsor when requested for periodic safety assessments, review of IND annual reports, review of IND safety reports, and preparation of final study reports. 12.4.2 SAEs All SAEs (regardless of relationship and whether or not they are also UPs) must be reported on the Safety Expedited Report Form (SERF) and sent to the Sponsor Clinical Safety Office (CSO) by [CONTACT_3719] e-mail attachment. Deaths and immediately life-threatening SAEs will be reported within [ADDRESS_1133746] INFORMATION:  Clinical Safety Office [ADDRESS_1133747] Frederick, MD [ZIP_CODE] Phone: [PHONE_070] Fax: [PHONE_016] E-mail: [EMAIL_007]   12.4.[ADDRESS_1133748] be reported to the CSO and sent by [CONTACT_3719] e-mail attachment using the NIH Problem Report Form no later than 7 calendar days of site awareness of the event. UPs that are not AEs are not reported to the Sponsor CSO. 12.4.4 Pregnancy  All pregnancies will be reported on the Pregnancy Notification/Outcome Form to the CSO within 1 business day from site awareness.  Pregnancy outcome data (e.g., delivery outcome, spontaneous or elective termination of the pregnancy) will be reported to the CSO within 3 business days of the site’s awareness.  Although pregnancy itself is not an AE, events that meet SAE criteria during pregnancy, delivery, or in the neonate (e.g., congenital anomaly/birth defect) are reportable on the SERF.  In the event of pregnancy, the following steps will be taken: • Discontinue the study agent and procedures but continue to follow-up for safety. • Unblind the subject. 
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 48 of 62 • Report to the DSMB and the IRB. • Advise the research subject to notify the obstetrician of study participation and study agent exposure. 12.[ADDRESS_1133749] that may require expedited reporting and/or safety evaluation include, but are not limited to: • Overdose of a study drug • Suspected abuse/misuse of a study drug • Inadvertent or accidental exposure to a study drug • Medication error involving a product (with or without subject/patient exposure to the study drug, e.g., name [CONTACT_2976])  Special reporting situations should be recorded. Any special reporting situation that meets the criteria of a serious adverse event should be recorded as a serious adverse event and reported as described in Section 12.4.2. 12.5.[ADDRESS_1133750] of the protocol will not be reported to the IRB unless they occur at a rate greater than anticipated by [CONTACT_3476]. Expected AEs will not be reported to the IRB unless they occur at a rate greater than that known to occur in vaccine recipi[INVESTIGATOR_840]. If the rate of these events exceeds the rate expected by [CONTACT_3476], the events will be classified and reported as though they are UPs. 12.5.4 Annual Reporting to the NIAID IRB The following items will be reported to the NIAID IRB in summary at the time of Continuing Review: • Serious and non-serious UPs  • Expected SAEs that are possibly, probably, or definitely related to the research • SAEs that are not related to the research • All AEs, except expected AEs granted a waiver of reporting • Serious and non-serious protocol deviations  • Serious, continuing, and minor non-compliance 
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 49 of 62 • Any trends or events which in the opi[INVESTIGATOR_52567] • A summary of accumulated safety data  12.6 Follow-Up of AEs and SAEs AEs that occur following enrollment of the participant (by [CONTACT_79844]) will be followed until the final outcome is known or until the end of the 10-month study follow-up period. AEs that have not resolved by [CONTACT_40738]-up period will be recorded as “ongoing.” Any participant who experiences complications due to vaccine/placebo administration will be followed until resolution of such complications or appropriate referral to the necessary medical care has been made.  SAEs that have not resolved by [CONTACT_1008]-up period will be followed until final outcome is known. If it is not possible to obtain a final outcome for an SAE (e.g., the participant is lost to follow-up), the reason a final outcome could not be obtained will be recorded by [CONTACT_673403].   SAEs that occur after the 10-month study follow-up period that are reported to and are assessed by [CONTACT_1010], probably, or definitely related will be reported to the CSO, as described above (Section 12.4.2). 12.7 Sponsor’s Reporting Responsibilities S[LOCATION_003]Rs as defined in [ADDRESS_1133751] in this study include any of the following: • A subject experiences an SAE that is possibly, probably, or definitely related to a study agent; • A subject experiences two Grade 3 or greater AEs that are possibly, probably, or definitely related to a study agent; • Any safety issue that the site investigator determines should pause administration of a study agent to a single subject.  The CSO, in collaboration with the principal investigator, may also pause for an entire group if a safety concern is identified. 
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 50 of 62 12.8.1 Reporting a Pause If a pausing criterion is met, a description of the AE(s) or safety issue must be reported by [CONTACT_458] [INVESTIGATOR_874] 1 business day to the CSO, the IRB, and the DSMB by [CONTACT_40743]. 12.8.2 Resumption of a Paused Study The CSO, in collaboration with the principal investigator [INVESTIGATOR_1238]/or the relevant DSMB, will determine whether or not it is safe to resume administration of the study agent to the subject. The principal investigator [INVESTIGATOR_818542].  A subject who does not resume study agent will continue to be followed for safety.  12.9 Halting Rules for the Protocol Halting the study requires immediate discontinuation of study agent administered for all subjects and suspension of enrollment until a decision is made whether or not to continue enrollment and study agent administration.  The halting rules are: • 1 or more subjects experience the same or similar SAEs that are possibly, probably, or definitely related to the study agent; OR • 2 or more of the same or similar AE in different subjects that are grade 3 or above and are possibly, probably, or definitely related to the study agent; OR • any safety issue that the principal investigator [INVESTIGATOR_1238]/or the CSO determines should halt the study.  The principal investigator [INVESTIGATOR_1238]/or CSO will determine if the study should be halted. In addition, the FDA may halt the study at any time following review of any safety concerns.   12.9.1 Reporting a Study Halt If a halting rule is met, a description of the AE(s) or safety issue must be reported by [CONTACT_458] [INVESTIGATOR_874] [ADDRESS_1133752] the right to terminate this study at any time.  Reasons for terminating the study may include, but are not limited to, the following: 1. The incidence or severity of AEs in this study indicates a potential health hazard to participants 2. Participant enrollment is unsatisfactory 3. Data recording is inaccurate or incomplete 4. Investigators do not adhere to the protocol, or applicable regulatory guidelines in conducting the study  The IRB, the NIAID, the FDA, or other government agencies, as part of their duties to ensure that research participants are protected may discontinue the study at any time. Subsequent review of serious, unexpected and related AEs by [CONTACT_1201], the DSMB, the sponsor, the FDA, and other regulatory authorities may also result in suspension of further trial interventions/administration of study agent at a site. The FDA, other regulatory authorities, and the study sponsor retain the authority to suspend additional enrollment and study agent administration for the entire study as applicable.   12.11 Premature Withdrawal of a Participant Participants may withdraw prior to vaccine administration and no further testing or follow up will be performed. The PI [INVESTIGATOR_818543]/he wants to prematurally withdraw from the study to determine the best course of action for the participant. If the participant would like to withdraw after vaccination, clinical laboratory tests and procedures for safety purposes will continue as obtainable and at a frequency determined by [CONTACT_978]. If the participant does not return for scheduled follow-up visits, the study staff will make every reasonable effort to contact [CONTACT_40744], mail, or email, or a combination of the latter and reiterate that follow-up visits are strongly encouraged for safety reasons.      An individual subject will be withdrawn for any of the following: • An individual subject’s decision. (The investigator should attempt to determine the reason for the subject’s decision.) • Non-compliance with study procedures to the extent that it is potentially harmful to the subject or to the integrity of the study data. • A change in the subject’s baseline condition after enrollment so that the subject no longer meets one or more of the inclusion/exclusion criteria. • The investigator determines that continued participation in the study would not be in the best interest of the subject. 
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 52 of 62 12.12  Replacement of a Participant  If a participant withdraws or appears ineligible to continue the study before vaccine/placebo administration, he/she will be removed and no data will be used in analysis or publication of the study. The participant may be replaced in the accrual with a new volunteer who qualifies and consents to the study.  If a participant does not receive 2 vaccinations, but does not withdraw from the study, that participant’s data may be used in the analysis, but an additional participant may be enrolled who qualifies and consents to the study to receive [ADDRESS_1133753] withdrawn will be used and included in the safety analysis.   12.13 Safety Oversight 12.13.1 Safety Review and Communications Plan (SRCP) A Safety Review and Communication Plan (SRCP) has been developed for the protocol. The SRCP is an internal communications document between the PI [INVESTIGATOR_40663], which delineates the safety oversight responsibilities of the PI, the CSO, and other stakeholders. The SRCP also includes the overall plan for conducting periodic safety surveillance assessments.  12.13.2 Sponsor Medical Monitor A Medical Monitor, representing the IND Sponsor (OCRPRO), has been appointed for oversight of safety in this clinical study. The Sponsor Medical Monitor will be responsible for performing routine safety assessments in an SRCP. 12.13.[ADDRESS_1133754] at the time pausing or halting criteria are met and obtain a recommendation concerning continuation, modification, or termination of the study. The PI [INVESTIGATOR_818544].  
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 53 of 62 13 Site Monitoring Plan According to the International Council on Harmonization (ICH) Good Clinical Practice (GCP) 5.18 and FDA 21 CFR 312.50, clinical protocols are required to be adequately monitored by [CONTACT_4530]. This study monitoring will be conducted according to the “NIAID Intramural Clinical Monitoring Guidelines.” Monitors under contract to the NIAID/OCRPRO will visit the clinical research site to monitor aspects of the study in accordance with the appropriate regulations and the approved protocol. The objectives of a monitoring visit will be: 1) to verify the existence of signed informed consent documents and documentation of the informed consent process for each monitored participant; 2) to verify the prompt and accurate recording of all monitored data points, and prompt reporting of all SAEs; 3) to compare clinical data abstracts with individual participants’ records and source documents (participants’ charts, laboratory analyses and test results, physicians’ progress notes, nurses’ notes, and any other relevant original participant information); and 4) to help ensure investigators are in compliance with the protocol. The monitors also will inspect the clinical site regulatory files to ensure that regulatory requirements (FDA and Office for Human Research Protections [OHRP]) and applicable guidelines (ICH-GCP) are being followed. During the monitoring visits, the investigator (and/or designee) and other study personnel will be available to discuss the study progress and monitoring visit.  The investigator (and/or designee) will make study documents (e.g., consent forms, clinical data abstracts, and pertinent hospi[INVESTIGATOR_893]) readily available for inspection by [CONTACT_1622], IRB, site monitors, and NIAID staff for confirmation of the study data.   A specific protocol monitoring plan will be discussed with the principal investigator [INVESTIGATOR_322063]. The plan will outline the frequency of monitoring visits based on such factors as study enrollment, data collection status, and regulatory obligations. 14 Statistical Considerations  14.1 Study Hypothesis The study hypothesis is that AGS-v specific total immunoglobulin will increase after vaccination with AGS-v or adjuvanted AGS-v and/or PBMCs collected after vaccination incubated with AGS-v antigens will show a greater Th1 response as measured by [CONTACT_14234]-gamma as compared to placebo vaccination. 14.2 Sample Size Justification and Analysis Plan The sample size for this study is based on the primary comparison of total immunoglobulin and interferon-gamma release with each of the experimental vaccine arms to placebo vaccine.  Since this is a Phase 1b study we are looking for activity of the vaccine that would indicate the vaccines should be studied further. Since we do not wish to expose more subjects than necessary to an experimental vaccine but we also don’t 
Universal Mosquito Vaccine Protocol Version 5.[ADDRESS_1133755] 90% power with a 1-sided type I error rate of .1. We also will not adjust for the 3 multiple comparisons  (all 3 arms being compared).   With 15 subjects per arm, there will be 90% power to detect a true difference in the primary efficacy endpoint of .[ADDRESS_1133756] with significance level of .1 (one sided).  For the safety endpoint we are interested in identifying AEs that may occur with the vaccines. With [ADDRESS_1133757] one AE  N=15 N=[ADDRESS_1133758] one event for various true underlying rates for 15 (single arm) or 30 
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 55 of 62 patients (collapse across experimental arms). Table 3 gives the detectable differences with 80% power.  Table 3. Difference in probabilities that can be detected with 80% power for sample sizes of 15 in each group or 15 in one group and 30 in the other 15 per arm 15 in arm 1 combined arms so n=[ADDRESS_1133759] 6 patients will be block randomized.  Once an interim safety analysis is done on the initial enrollment, the remaining 39 patients will be randomized and enrolled in appropriately sized cohorts until there are 15 patients per arm. 15 Ethics/Protection of Human Participants 15.1 Informed Consent Process Informed consent is a process where information is presented to enable persons to voluntarily decide whether or not to participate as a research participant. It is an ongoing conversation between the human research participant and the researchers, which begins before consent is given and continues until the end of the participant’s involvement in the research. Discussions about the research will provide essential information about the study and include: purpose, duration, experimental procedures, alternatives, risks, and benefits. Participants will be given the opportunity to ask questions and have them answered.   The participants will sign the informed consent document prior to undergoing any procedures. The participant may withdraw consent at any time throughout the course of the trial. A copy of the informed consent document will be given to the participants for their records. The researcher will document the signing of the consent form in the participant’s medical record. The rights and welfare of the participant will be protected by [CONTACT_34693].       
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 56 of 62 15.2 Non–English-Speaking Participants If a non–English-speaking participant is unexpectedly eligible for enrollment, the participant will be provided with the CC Short Written Consent Form for Non–English-Speaking Research Participants in the participant’s native language and a verbal explanation of the purpose, procedures and risks of the study as described in MAS Policy M77-2, NIH HRPP SOP 12, and 45 CFR 46.117(b)(2). The IRB-approved English consent form will serve as basis for the verbal explanation of the study. The investigator will obtain an interpreter unless the investigator is fluent in the prospective participant’s language. Preferably, the interpreter will be someone who is independent of the participant (i.e., not a family member). Interpreters provided by [CONTACT_79849]. The interpreters will translate the IRB-approved English consent form verbatim and facilitate discussion between the participant and investigator.  The IRB-approved English consent form will be signed by [CONTACT_83194] a witness to the oral presentation. The CC Short Written Consent Form will be signed by [CONTACT_4538] a witness who observed the presentation of information. The interpreter may sign the consent document as the witness and, in this case, will note “Interpreter” under the signature [CONTACT_4548]. A copy of both signed forms will be provided to the participant to take home.  The investigator obtaining consent will document the consent process in the participant’s medical record (CRIMSON), including the name [CONTACT_4549]. Further, all instances of use of the CC Short Written Consent Form will be reported to the IRB at the time of annual review. If the CC Short Written Consent Form is used three times or more for the same language within an IRB approval period, this will be reported to the IRB immediately. 15.[ADDRESS_1133760] all documents and records required to be maintained by [CONTACT_093], including but not limited to medical records. Records will be kept in secure electronic systems. Clinical information will not be released without written permission of the participant, except as necessary for monitoring by [CONTACT_1744], the FDA, the NIAID, the OHRP, or the sponsor’s designee. [ADDRESS_1133761] Keepi[INVESTIGATOR_007] 16.1 Data Capture and Management Study data will be collected and maintained in CRIMSON and CRIS and collected directly from participants during study visits and telephone calls. Source documents include all recordings of observations or notations of clinical activities and all reports and records necessary to confirm the data abstracted for this study. Data entry into these systems will be performed by [CONTACT_4539]. The Investigator is responsible for 
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 57 of 62 assuring that the data collected are complete, accurate, and recorded in a timely manner.  Data that may potentially unblind the vaccine assignment (e.g., vaccine preparation/accountability data, and vaccine allocation) will be handled with special care to ensure that the integrity of the blind is maintained and the potential for bias is minimized. This can include making special provisions, such as segregating the data in question from view by [CONTACT_473], sponsor clinical team, or others as appropriate until the time of database lock and unblinding. 16.[ADDRESS_1133762]. All stored records will be kept confidential to the extent required by [CONTACT_1032], state, and local law.   Should the investigator wish to assign the study records to another party and/or move them to another location, the investigator will provide written notification of such intent to OCRPRO/NIAID with the name [CONTACT_40756]/or their new location. Destruction or relocation of research records will not proceed without written permission from NIAID/OCRPRO. 
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 58 of 62 SCIENTIFIC REFERENCES  1. World Malaria Report 2015. World Health Organization;2015. 2. Bhattarai A, Ali AS, Kachur SP, et al. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS medicine. 2007;4(11):e309. 3. Najera JA, Gonzalez-Silva M, Alonso PL. Some lessons for the future from the Global Malaria Eradication Programme (1955-1969). PLoS medicine. 2011;8(1):e1000412. 4. Rts SCTP. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS medicine. 2014;11(7):e1001685. 5. Greenwood B, Targett G. Do we still need a malaria vaccine? Parasite immunology. 2009;31(9):582-586. 6. Ribeiro JM. Role of saliva in blood-feeding by [CONTACT_40750]. Annual review of entomology. 1987;32:463-478. 7. Wasserman HA, Singh S, Champagne DE. Saliva of the Yellow Fever mosquito, Aedes aegypti, modulates murine lymphocyte function. Parasite immunology. 2004;26(6-7):295-306. 8. Cross ML, Cupp EW, Enriquez FJ. Differential modulation of murine cellular immune responses by [CONTACT_818579]. The American journal of tropi[INVESTIGATOR_40667]. 1994;51(5):690-696. 9. Silvestre R, Cordeiro-Da-Silva A, Santarem N, Vergnes B, Sereno D, Ouaissi A. SIR2-deficient Leishmania infantum induces a defined IFN-gamma/IL-10 pattern that correlates with protection. Journal of immunology. 2007;179(5):3161-3170. 10. Peng Z, Yang M, Simons FE. Immunologic mechanisms in mosquito allergy: correlation of skin reactions with specific IgE and IgG antibodies and lymphocyte proliferation response to mosquito antigens. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 1996;77(3):238-244. 11. Peng Z, Simons FE. Mosquito allergy: immune mechanisms and recombinant salivary allergens. International archives of allergy and immunology. 2004;133(2):198-209. 12. Torre D, Speranza F, Giola M, Matteelli A, Tambini R, Biondi G. Role of Th1 and Th2 cytokines in immune response to uncomplicated Plasmodium falciparum malaria. Clinical and diagnostic laboratory immunology. 2002;9(2):348-351. 13. Donovan MJ, Messmore AS, Scrafford DA, Sacks DL, Kamhawi S, McDowell MA. Uninfected mosquito bites confer protection against infection with malaria parasites. Infection and immunity. 2007;75(5):2523-2530. 14. Sidjanski S, Vanderberg JP. Delayed migration of Plasmodium sporozoites from the mosquito bite site to the blood. The American journal of tropi[INVESTIGATOR_40667]. 1997;57(4):426-429. 
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 59 of 62 15. Ponnudurai T, Lensen AH, van Gemert GJ, Bolmer MG, Meuwissen JH. Feeding behaviour and sporozoite ejection by [CONTACT_818580]. Transactions of the Royal Society of Tropi[INVESTIGATOR_177888]. 1991;85(2):175-180. 16. Vanderberg JP, Stewart MJ. Plasmodium sporozoite-host cell interactions during sporozoite invasion. Bulletin of the World Health Organization. 1990;[ADDRESS_1133763]:74-79. 17. Vanderberg JP, Chew S, Stewart MJ. Plasmodium sporozoite interactions with macrophages in vitro: a videomicroscopic analysis. The Journal of protozoology. 1990;37(6):528-536. 18. Krettli AU, Dantas LA. Which routes do Plasmodium sporozoites use for successful infections of vertebrates? Infection and immunity. 2000;68(5):3064-3065. 19. Thangamani S, Higgs S, Ziegler S, Vanlandingham D, Tesh R, Wikel S. Host immune response to mosquito-transmitted chikungunya virus differs from that elicited by [CONTACT_40752]. PloS one. 2010;5(8):e12137. 20. Schneider BS, Higgs S. The enhancement of arbovirus transmission and disease by [CONTACT_818581]. Transactions of the Royal Society of Tropi[INVESTIGATOR_177888]. 2008;102(5):400-408. 21. Brennan JD, Kent M, Dhar R, Fujioka H, Kumar N. Anopheles gambiae salivary gland proteins as putative targets for blocking transmission of malaria parasites. Proceedings of the National Academy of Sciences of the [LOCATION_002] of America. 2000;97(25):[ZIP_CODE]-[ZIP_CODE]. 22. Suneja A, Gulia M, Gakhar SK. Blocking of malaria parasite development in mosquito and fecundity reduction by [CONTACT_40754] (Diptera: Culicidae). Archives of insect biochemistry and physiology. 2003;52(2):63-70. 23. Gulia M, Suneja A, Gakhar SK. Effect of anti-mosquito hemolymph antibodies on fecundity and on the infectivity of malarial parasite Plasmodium vivax to Anopheles stephensi (Diptera:Insecta). Japanese journal of infectious diseases. 2002;55(3):78-82. 24. Stoloff GA, Caparros-Wanderley W. Synthetic multi-epi[INVESTIGATOR_818545]. European journal of immunology. 2007;37(9):2441-2449. 25. Vaughan JA, Scheller LF, Wirtz RA, Azad AF. Infectivity of Plasmodium berghei sporozoites delivered by [CONTACT_40755]: implications for sporozoite vaccine trials. Infection and immunity. 1999;67(8):4285-4289. 26. Valenzuela JG, Belkaid Y, Garfield MK, et al. Toward a defined anti-Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein. The Journal of experimental medicine. 2001;194(3):331-342. 27. Belkaid Y, Kamhawi S, Modi G, et al. Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in 
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 60 of 62 the mouse ear dermis. The Journal of experimental medicine. 1998;188(10):1941-1953. 28. Wu Y, Ellis RD, Shaffer D, et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PloS one. 2008;3(7):e2636. 29. National Institutes of Health: Giving a subcutaneous injection 2015; http://www.cc.nih.gov/ccc/patient_education/pepubs/subq.pdf, 2016. 30. Bartlett JA, Wasserman SS, Hicks CB, et al. Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative. AIDS. 1998;12(11):1291-1300. 31. Graham BS, McElrath MJ, Keefer MC, et al. Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity. PloS one. 2010;5(8):e11995. 32. Pi[INVESTIGATOR_190494], Berzofsky JA, Fowke KR, et al. HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. AIDS. 1999;13(15):2003-2012. 33. Trauger RJ, Daigle AE, Giermakowska W, Moss RB, Jensen F, Carlo DJ. Safety and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: results of a double-blind, adjuvant controlled trial. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;[ADDRESS_1133764] 2:S74-82. 34. Trauger RJ, Ferre F, Daigle AE, et al. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells. The Journal of infectious diseases. 1994;169(6):1256-1264. 
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 61 of 62 Appendix A: Schedule of Procedures/Evaluations Study Phase > Screen Injection 1   Injection 2   Feeding Telephone Call Follow Up Study Day > ~ DAY -60 D0 D7 ± 2 days D14 ± 2 days D21 D28 ± 2 days D35 ± 2 days D42 +14 days  1 visit every 60 days (± 14 days) Under Protocol 11-I-0183 Day 44                     Outpatient Visit  X X X X X X X  X Written Consent  X         Medical/Medication History  X X X X X X X  X Assessment and PE  X X X X X X X  X Review of I/E criteria and review of consent  X         Vital signs †  X X X X X X X  X Review of Diary Card   X   X     Telephone Call to Assess Symptoms         X  Pregnancy test‡  X X X X X X X  X Urinalysis  X X X X X X X  X Vaccine administration  X   X      Randomization  X         Mosquito Feeding        X   CBC + diff  X X X X X X X  X Acute Care, Mineral, and Hepatic Panels  X X X X X X X  X LDH, Uric Acid, Creatine Kinase, and Total Protein  X X X X X X X  X Serum/Whole Blood Collection  X   X   X  X IgE  X          †Vital Signs: participants must be sitting for a minimum of 5 minutes prior to these procedures being performed; vital signs include blood pressure, mean arterial pressure, heart rate, respi[INVESTIGATOR_697], temperature, weight, pulse oximetry; height will be taken at the screening visit only.   ‡Serum pregnancy testing at the screening and all other visits. On Days 0, 21, 42, study vaccination or mosquito feeding will not be initiated until results are available. Females only.  
Universal Mosquito Vaccine Protocol Version 5.0 09 Feb, 2018  
Page 62 of 62 Appendix B: Blood Volumes for Specimen Collection    Study Schedule/Procedures           Day 0 Day 7 (+/- 2 days) Day 14 (+/- 2 days) Day 21 (+/- 2 days) Day 28 (+/- 2 days) Day 35 (+/- 2 days) Day 42 (+ 14 days) 1 visit every 60 days (+/- 14 days) b-hCG, Pregnancy 4mL per blood draw 4 mL 4 mL 4 mL 4 mL  4 mL 4 mL 4 mL 4 mL CBC + Diff  3mL per blood draw 3 mL 3 mL 3 mL 3 mL 3 mL 3 mL 3 mL 3 mL Serum/Whole Blood Collection  8mL x2 for serum, 8ml x2 for whole blood, and 2.5 mL for RNA per blood draw    8mL x2 for serum, 8ml x2 for whole blood, and 2.5 mL for RNA per blood draw     Acute Care, Mineral, and Hepatic Panels,  4mL per blood draw 4 mL 4 mL 4 mL 4 mL 4 mL 4 mL 4 mL 4 mL   LDH, Uric Acid, Creatine Kinase, and Total Protein Included with the above panels X X X X X X X X IgE, Total 4mL per blood draw 4 mL        Serum/Whole Blood Collection 8 mL X 1 for serum, 8.5 mL X 5 for whole blood, and 2.5 mL for RNA per blood draw  53 mL + 8.[ADDRESS_1133765] feeding   53 mL     
Daily Volume (mL)  110.[ADDRESS_1133766] follow up,1152mL over the course of the whole study 